Diuretics: still essential drugs for the management of hypertension

References

• Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Fuchs FD. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure. Expert Rev. Cardiovasc. Ther.2(5), 771–775 (2004).
   PubMedGoogle Scholar
• Smith RE, Ashiya M. Antihypertensive therapies. Nat. Rev. Drug Discov.6, 597–598 (2007).
   PubMed Web of Science ®Google Scholar
• Fuchs FD. The corporate bias and the molding of prescription practices: a case study in hypertension. Braz. J. Med. Biol. Res.42, 224–228 (2009).
   PubMed Web of Science ®Google Scholar
• Horton R. Postpublication criticism and the shaping of clinical knowledge. JAMA287, 2843–2847 (2002).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA289, 2560–2571 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. ESH–ESC Task Force on the Management of Arterial Hypertension. 2007 ESH–ESC Practice Guidelines for the Management of Arterial Hypertension. J. Hypertens.25, 1751–1762 (2007).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA). Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359, 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA202, 1028–1034 (1967).
   PubMed Web of Science ®Google Scholar
• Fuchs FD, Klag MJ, Whelton PK. The classics: a tribute to the fiftieth anniversary of the randomized clinical trial. J. Clin. Epidemiol.53, 335–342 (2000).
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet335, 827–838 (1990).
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA265, 3255–3264 (1991).
   PubMed Web of Science ®Google Scholar
• MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults. Br. Med. J.304, 405–412 (1992).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP–Hypertension). Lancet338, 1281–1285 (1991).
   PubMed Web of Science ®Google Scholar
• Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of Mild Hypertension Study (TOMHS): final results. JAMA270, 713–724 (1993).
   PubMed Web of Science ®Google Scholar
• Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension35, 1025–1030 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindoholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet353, 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet356, 359–365 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindoholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet354, 1751–1756 (1999).
   PubMed Web of Science ®Google Scholar
• Fuchs FD. What does STOP-2 tell us about management of hypertension? Lancet355, 651 (2000).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C, Chalmers J, Woodward M, MacMahon S. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet362, 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Fuchs FD. Effects of different blood-pressure-lowering regimens on major cardiac events. Lancet363, 332 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Fuchs FD. Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. Lancet359, 2203 (2002).
   PubMed Web of Science ®Google Scholar
• Fuchs FD, Gus M, Ribeiro JP. ASCOT-BPLA. Lancet367, 205 (2006).
   PubMed Web of Science ®Google Scholar
• Kato J, Eto T. Diuretics in the LIFE study. Lancet364, 413 (2004).
   PubMed Web of Science ®Google Scholar
• Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine–selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ326, 1171–1173 (2003).
   PubMed Web of Science ®Google Scholar
• Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study (INSIGHT). Lancet356, 366–372 (2000).
   PubMed Web of Science ®Google Scholar
• Mancia G, Brown M, Castaigne A et al.; INSIGHT. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension41, 431–436 (2003).
   PubMed Web of Science ®Google Scholar
• Fuchs FD. May we die twice? Hypertension42, e8 (2003).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet363, 2049–2051 (2004).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist ibesartan in patients with nephropathy due type diabetes. N. Engl. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of ibesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med.345, 870–878 (2001).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345(12), 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Svensson P, Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension38, e28–e32 (2001).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet358, 1305–1315 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrari R; Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch. Intern. Med.166, 659–666 (2006).
   PubMed Web of Science ®Google Scholar
• Fuchs FD. It is time to stop comparing blood pressure-lowering drugs with placebo. Arch. Intern. Med.166, 1786 (2006).
   PubMedGoogle Scholar
• Patel A; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet370, 829–840 (2007).
   PubMed Web of Science ®Google Scholar
• Fuchs FD. The ADVANCE trial. Lancet371, 25 (2008).
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA.288, 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Dunn JK, Cutler JA et al.; ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA293, 1595–1608 (2005).
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Harris-Haywood S, Pressel S et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.168, 207–217 (2008).
   PubMedGoogle Scholar
• Rahman M, Pressel S, Davis BR et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.165, 936–946 (2005).
   PubMed Web of Science ®Google Scholar
• Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.166, 2191–2201 (2006).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358, 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Fuchs FD, Guerrero P, Gus M. What is next when the first blood pressure-lowering drug is not sufficient? Expert Rev. Cardiovasc. Ther.5(3), 435–439 (2007).
   PubMedGoogle Scholar
• Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA259, 1976–1982 (1988).
   PubMed Web of Science ®Google Scholar
• Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone. Hypertension43, 4–9 (2004).
   PubMed Web of Science ®Google Scholar
• Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA.292, 43–44 (2004).
   PubMed Web of Science ®Google Scholar
• Mortality after 10.5 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation82, 1616–1628 (1990).
   PubMed Web of Science ®Google Scholar
• Ernst ME, Carter BL, Goerdt CJ et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension47, 352–358 (2006).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med.358, 1887–1898 (2008).
   PubMed Web of Science ®Google Scholar
• Fuchs FD. Diuretics: drugs of choice for the initial management of patients with hypertension. Expert Rev. Cardiovasc. Ther.1(1), 35–41 (2003).
   PubMedGoogle Scholar